For children with severe hypertrophic cardiomyopathy caused by gain-of-function RAS/mitogen-activated protein kinase (MAPK) mutations (RASopathy), trametinib reduces mortality and morbidity.

Affected children are born with café-au-lait spots and sometimes Lisch nodules. During adolescence and young adulthood, more than 19% of affected individuals with NF1 develop cutaneous neurofibromas ...

A phase 2a trial of IMM-1-104 plus chemotherapy demonstrated efficacy and tolerability in first- and second-line pancreatic ...

Trametinib, a mitogen-activated protein kinase (MEK) inhibitor, reduces mortality and morbidity in children with severe hypertrophic cardiomyopathy (HCM) caused by pathogenic variants in the RAS/MAPK ...

“The response rates emerging from both of our Phase 2a combination arms in first-line pancreatic cancer are comparable to one ...

Pasithea Therapeutics opens European clinical trial sites and completes initial dosing of cohort 4: Miami Thursday, January 16, 2025, 12:00 Hrs [IST] Pasithea Therapeutics Corp., ...

MIAMI, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical ...

Combined MEK and PI3K inhibition has had limited success in the clinic, although alternative methods of targeting these pathways may be effective. MEK inhibitors form the backbone of multiple ...

At this time, VSTM lives and dies on the fortunes of their inhibitor of MAPK signaling by deactivating the "downstream" regulators RAF and MEK, serving to choke off excess MAPK signaling (which ...